Inovio announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate targeting Zaire Ebola virus, as a booster in healthy adult participants who previously received a single injection of Ervebo. In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% of 36 treated participants. INO-4201 was evaluated in a Phase 1b trial to assess its safety, tolerability, and immunogenicity in healthy adult participants who previously received a single injection of Ervebo, a vaccine approved by the FDA for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. The trial was designed to test whether INO-4201 can be used as a booster in healthy participants previously vaccinated with Ervebo.
Published first on TheFly
